

PA Criteria	Criteria Details						
Covered Uses (FDA approved indication)	Spevigo is an interleukin-36 receptor antagonist indicated for the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients 12 years of age and older and weighing at least 40 kg.						
Exclusion Criteria	Must not be used in combination with other biologic or targeted DMARDS or with Otezla.						
Required Medical Information	<p>For GPP requests: Medical records supporting the request must be provided;</p> <ol style="list-style-type: none"> 1. Patient has a diagnosis of generalized pustular psoriasis (GPP) confirmed by a skin biopsy, presence of systemic symptoms such as fever and fatigue, and relapsing episodes (history of GPP flares); 2. Patient is experiencing a GPP flare of moderate-to-severe intensity defined by all the following (a, b, c, and d): <ol style="list-style-type: none"> a. a Generalized Pustular Psoriasis Physician Global Assessment (GPPPGA) total score of three or more; b. New or worsening pustules; c. a GPPPGA pustulation sub-score of two or more; and d. 5% of more of body surface area (BSA) with erythema and pustules 						
Age Restriction	Must be age 12 or older.						
Prescriber Restrictions	Prescriber is a specialist or has consulted with a specialist for the condition being treated.						
Coverage Duration	Initial: 12 weeks. Dose will be approved according to the FDA approved labeling or within accepted standards of medical practice.						
Other Criteria/Information	<p>Refer to the Gold Coast Health Plan Medicare Part B Reference and Summary of Evidence document.</p> <table border="1"> <thead> <tr> <th>HCPCS</th> <th>Description</th> <th>Billing Units/How Supplied</th> </tr> </thead> <tbody> <tr> <td>J1747</td> <td>Spevigo (spesolimab-sbzo)</td> <td>Billing unit: 1 mg 450 mg/7.5 ml SDV</td> </tr> </tbody> </table>	HCPCS	Description	Billing Units/How Supplied	J1747	Spevigo (spesolimab-sbzo)	Billing unit: 1 mg 450 mg/7.5 ml SDV
HCPCS	Description	Billing Units/How Supplied					
J1747	Spevigo (spesolimab-sbzo)	Billing unit: 1 mg 450 mg/7.5 ml SDV					

STATUS	DATE REVISED	REVIEW DATE	APPROVED/REVIEWED BY	EFFECTIVE DATE
Created	3/26/2025	3/26/2025	Dawn Shojai, PharmD, Senior Pharmacy Benefit Consultant (PSG)	N/A
Approved	N/A	5/15/2025	Pharmacy & Therapeutics (P&T) Committee	5/15/2025